Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
69
CNTB Quote, Financials, Valuation and Earnings
Last price:
$2.67
Seasonality move
:
18.52%
Day range:
$2.65 - $2.89
52-week range:
$0.51 - $3.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.72x
P/B ratio:
2.72x
Volume:
60.5K
Avg. volume:
489K
1-year change:
177.32%
Market cap:
$150.4M
Revenue:
$26M
EPS (TTM):
-$0.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNTB
Connect Biopharma Holdings Ltd.
|
-- | -$0.24 | -100% | -62.99% | $7.90 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
PBYI
Puma Biotechnology, Inc.
|
$51M | $0.09 | 16.12% | -41.13% | $3.50 |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -- | -- | -- | $6.67 |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNTB
Connect Biopharma Holdings Ltd.
|
$2.69 | $7.90 | $150.4M | -- | $0.00 | 0% | 5.72x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
PBYI
Puma Biotechnology, Inc.
|
$6.16 | $3.50 | $310.4M | 8.32x | $0.00 | 0% | 1.46x |
|
RLMD
Relmada Therapeutics, Inc.
|
$4.51 | $6.67 | $330.7M | -- | $0.00 | 0% | -- |
|
SPRO
Spero Therapeutics, Inc.
|
$2.32 | $4.00 | $130.7M | 10.75x | $0.00 | 0% | 4.40x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNTB
Connect Biopharma Holdings Ltd.
|
-- | 0.906 | -- | 11.85x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 1.268 | 15.34% | 1.57x |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | 8.312 | -- | 2.68x |
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 12.710 | 3.17% | 3.63x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNTB
Connect Biopharma Holdings Ltd.
|
-- | -$17.7M | -- | -- | -- | -$10M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -$10.3M | -214.4% | -214.4% | -- | -$6.7M |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
Connect Biopharma Holdings Ltd. vs. Competitors
-
Which has Higher Returns CNTB or AIM?
AIM ImmunoTech has a net margin of -- compared to Connect Biopharma Holdings Ltd.'s net margin of -10571.43%. Connect Biopharma Holdings Ltd.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CNTBConnect Biopharma Holdings Ltd.-- -$0.31 $110.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CNTB or AIM?
Connect Biopharma Holdings Ltd. has a consensus price target of $7.90, signalling upside risk potential of 193.68%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Connect Biopharma Holdings Ltd., analysts believe AIM ImmunoTech is more attractive than Connect Biopharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CNTBConnect Biopharma Holdings Ltd.5 0 0 AIMAIM ImmunoTech1 0 0 -
Is CNTB or AIM More Risky?
Connect Biopharma Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CNTB or AIM?
Connect Biopharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Connect Biopharma Holdings Ltd. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNTB or AIM?
Connect Biopharma Holdings Ltd. quarterly revenues are $16K, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Connect Biopharma Holdings Ltd.'s net income of -$17.2M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Connect Biopharma Holdings Ltd.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Connect Biopharma Holdings Ltd. is 5.72x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNTBConnect Biopharma Holdings Ltd.5.72x -- $16K -$17.2M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CNTB or CVM?
CEL-SCI Corp. has a net margin of -- compared to Connect Biopharma Holdings Ltd.'s net margin of --. Connect Biopharma Holdings Ltd.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital CNTBConnect Biopharma Holdings Ltd.-- -$0.31 $110.5M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About CNTB or CVM?
Connect Biopharma Holdings Ltd. has a consensus price target of $7.90, signalling upside risk potential of 193.68%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Connect Biopharma Holdings Ltd., analysts believe CEL-SCI Corp. is more attractive than Connect Biopharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CNTBConnect Biopharma Holdings Ltd.5 0 0 CVMCEL-SCI Corp.1 0 0 -
Is CNTB or CVM More Risky?
Connect Biopharma Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock CNTB or CVM?
Connect Biopharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Connect Biopharma Holdings Ltd. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNTB or CVM?
Connect Biopharma Holdings Ltd. quarterly revenues are $16K, which are larger than CEL-SCI Corp. quarterly revenues of --. Connect Biopharma Holdings Ltd.'s net income of -$17.2M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Connect Biopharma Holdings Ltd.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Connect Biopharma Holdings Ltd. is 5.72x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNTBConnect Biopharma Holdings Ltd.5.72x -- $16K -$17.2M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns CNTB or PBYI?
Puma Biotechnology, Inc. has a net margin of -- compared to Connect Biopharma Holdings Ltd.'s net margin of 16.24%. Connect Biopharma Holdings Ltd.'s return on equity of -- beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital CNTBConnect Biopharma Holdings Ltd.-- -$0.31 $110.5M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About CNTB or PBYI?
Connect Biopharma Holdings Ltd. has a consensus price target of $7.90, signalling upside risk potential of 193.68%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -43.18%. Given that Connect Biopharma Holdings Ltd. has higher upside potential than Puma Biotechnology, Inc., analysts believe Connect Biopharma Holdings Ltd. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNTBConnect Biopharma Holdings Ltd.5 0 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is CNTB or PBYI More Risky?
Connect Biopharma Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.
-
Which is a Better Dividend Stock CNTB or PBYI?
Connect Biopharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Connect Biopharma Holdings Ltd. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNTB or PBYI?
Connect Biopharma Holdings Ltd. quarterly revenues are $16K, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Connect Biopharma Holdings Ltd.'s net income of -$17.2M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Connect Biopharma Holdings Ltd.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Connect Biopharma Holdings Ltd. is 5.72x versus 1.46x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNTBConnect Biopharma Holdings Ltd.5.72x -- $16K -$17.2M PBYIPuma Biotechnology, Inc.1.46x 8.32x $54.5M $8.8M
-
Which has Higher Returns CNTB or RLMD?
Relmada Therapeutics, Inc. has a net margin of -- compared to Connect Biopharma Holdings Ltd.'s net margin of --. Connect Biopharma Holdings Ltd.'s return on equity of -- beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.
Company Gross Margin Earnings Per Share Invested Capital CNTBConnect Biopharma Holdings Ltd.-- -$0.31 $110.5M RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M -
What do Analysts Say About CNTB or RLMD?
Connect Biopharma Holdings Ltd. has a consensus price target of $7.90, signalling upside risk potential of 193.68%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 47.82%. Given that Connect Biopharma Holdings Ltd. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Connect Biopharma Holdings Ltd. is more attractive than Relmada Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNTBConnect Biopharma Holdings Ltd.5 0 0 RLMDRelmada Therapeutics, Inc.2 1 0 -
Is CNTB or RLMD More Risky?
Connect Biopharma Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.740, suggesting its less volatile than the S&P 500 by 25.972%.
-
Which is a Better Dividend Stock CNTB or RLMD?
Connect Biopharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Connect Biopharma Holdings Ltd. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNTB or RLMD?
Connect Biopharma Holdings Ltd. quarterly revenues are $16K, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Connect Biopharma Holdings Ltd.'s net income of -$17.2M is lower than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Connect Biopharma Holdings Ltd.'s price-to-earnings ratio is -- while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Connect Biopharma Holdings Ltd. is 5.72x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNTBConnect Biopharma Holdings Ltd.5.72x -- $16K -$17.2M RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M
-
Which has Higher Returns CNTB or SPRO?
Spero Therapeutics, Inc. has a net margin of -- compared to Connect Biopharma Holdings Ltd.'s net margin of -242.19%. Connect Biopharma Holdings Ltd.'s return on equity of -- beat Spero Therapeutics, Inc.'s return on equity of -107.04%.
Company Gross Margin Earnings Per Share Invested Capital CNTBConnect Biopharma Holdings Ltd.-- -$0.31 $110.5M SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M -
What do Analysts Say About CNTB or SPRO?
Connect Biopharma Holdings Ltd. has a consensus price target of $7.90, signalling upside risk potential of 193.68%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 72.41%. Given that Connect Biopharma Holdings Ltd. has higher upside potential than Spero Therapeutics, Inc., analysts believe Connect Biopharma Holdings Ltd. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNTBConnect Biopharma Holdings Ltd.5 0 0 SPROSpero Therapeutics, Inc.0 1 0 -
Is CNTB or SPRO More Risky?
Connect Biopharma Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.482, suggesting its more volatile than the S&P 500 by 48.19%.
-
Which is a Better Dividend Stock CNTB or SPRO?
Connect Biopharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Connect Biopharma Holdings Ltd. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNTB or SPRO?
Connect Biopharma Holdings Ltd. quarterly revenues are $16K, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Connect Biopharma Holdings Ltd.'s net income of -$17.2M is lower than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Connect Biopharma Holdings Ltd.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Connect Biopharma Holdings Ltd. is 5.72x versus 4.40x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNTBConnect Biopharma Holdings Ltd.5.72x -- $16K -$17.2M SPROSpero Therapeutics, Inc.4.40x 10.75x $3M -$7.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
